MEDICORTEX

Bring clarity to brain injury.

Revolutionizing Brain Injury Diagnostics with a Rapid PoC Test

www.medicortex.eu

Medicortex Finland Oyj is now a subsidiary of Medicortex International AB (publ).

Medicortex International owns 89.9% of Medicortex Finland.
Medicortex Finland continues its R&D operations from Turku, Finland.

Together with other subsidiaries constituting the

Medicortex Group

October 2026

Statements in this presentation constitute “forward-looking” statements. These statements, which generally describe the objectives, plans, or goals of Medicortex International AB, may involve risks and uncertainties that could cause actual results to differ materially from those stated or implied in this context.

Traumatic Brain Injury: A Global Problem

Traumatic Brain Injury (TBI) occurs after a blow, jolt or blast to the head. It causes immediate physical damage to brain tissue.

A TBI can happen to anyone, anywhere and anytime.

69M

New TBI cases worldwide each year[1]

~90%

Of those injuries are **mild TBI** - also known as concussions[2]

Mild TBIs

<30 mins of unconsciousness
Glasgow Coma Score of 13-15
<24h of Post-Traumatic Amnesia



In Europe, 2.5 million people suffer a TBI each year[3]

[1] *J Neurosurg. 2018; Apr 27;130(4):1080-1097.*

[2] *Lancet Neurol 2022; 21: 1004–60.*

[3] *https://www.center-tbi.eu*

MEDICORTEX

Brain injury is still hard to detect.

There is a gap in the diagnostic toolkit for mild TBIs.

NEUROLOGICAL EXAMINATION

Relies on the patient's responses and is open to interpretation.

COMPUTED TOMOGRAPHY (CT) AND MAGNETIC RESONANCE IMAGING (MRI)

Not sensitive enough for mild injuries which frequently leave no visible lesion even when brain cells have been damaged.

BLOOD PROTEIN TESTS

Typically require a hospital environment, lab equipment and are invasive



MEDICORTEX

Our Solution:
A lab result, at the point of injury.

No imaging. No laboratory. No waiting.
Medicortex is developing a rapid, non-invasive, point-of-injury test for TBI.

Non-invasive sample
Urine or saliva sample: comfortable for adults and children alike.

Result in minutes
Point-of-injury read at the bedside or on the sideline.

Simple to interpret
Positive or negative: no training or instrument required.

Proprietary biomarkers
Glycans; carbohydrates released into body fluids after brain cell damage.

Clinical data from three studies
Biomarkers identified in TBI patients.

Built on IP
Protected by a portfolio of 7 patents. ProbTBI® trademarked.

MEDICORTEX

ProbTBI® – Urine-Based TBI Test Prototype

A handheld lateral flow prototype designed to detect TBI-associated glycan biomarkers in urine, providing the foundation for a rapid, non-invasive diagnostic test for traumatic brain injury.

Developed with support from the U.S. Department of Defense*



* Currently known as the Department of War

MEDICORTEX

Advantages that ProbTBI® test will provide

- Fast
- Portable
- Affordable



- Easy to use
- Patient friendly
- No radiation or contrast agent exposure


MEDICORTEX

Saliva-Based Test – In Development



Medicortex is developing a rapid glycan detection test for saliva samples – applicable for self-testing – on the same biomarker platform.


Developed with support from the U.S. Department of Defense*



* Currently known as the Department of War

MEDICORTEX

Product Timeline*



FUNDING: Investor & grant funding

PARTNERSHIPS: Manufacturing & distribution partners

* Subject to financing

** A device for near-patient testing (without self-testing) belongs to Class B in the IVD Regulation 2017/746.

MEDICORTEX

TBI Market

Global TBI biomarkers market expected to reach $4.7 billion by 2033


DRIVERS OF MARKET GROWTH

Population Growth & Aging
↑ Larger at-risk population

Road & Vehicle Use
↑ Road traffic and vehicle exposure

Active Lifestyles
↑ Sports & recreational activities

Better Detection
↑ Clinical recognition & classification of TBI



Source: Grand View Research

MEDICORTEX

Targeting B2B & B2C Markets

Medicortex is targeting institutional customers and B2C channels.

Emergency & Healthcare

Hospitals & Emergency Departments
Paramedics & First Responders

Institutional Care

Schools
Nursing & Care Facilities

Defense & Public Sector

Military & Defense Organizations

Commercial & Strategic Partners

Insurance Companies
Pharmaceutical Companies
Sports Organizations

B2C/Retail Channels

Pharmacies, OTC

Competition


ProbTBI® combines ease of use with non-invasiveness

Blood-based tests:

- **NanoDx:** NanoDx Tbit (electricity-dependent)
- **ABCDx:** TBICheck
- **Glia Diagnostics**
- **Abbott:** i-STAT TBI

Saliva-based tests:

- **Conan MedTech**
- **Marker:** MDx.100 (laboratory environment required)



MEDICORTEX

Exit Strategy: Dual-track approach

- **Targets:** Tier-1 diagnostic leaders (Roche, Abbott, Danaher, Siemens)
- **Path:** Strategic partnerships or M&A upon completion of a multi-center clinical trial or regulatory approval (FDA/CE)
- **Objective:** Full acquisition of IP and technology rights

Strategic Value for Acquirer / Partner

- **Unique Asset:** Designed to be the first non-invasive point-of-injury test for mild TBI
- **Defensibility:** Strong global patent portfolio (IP protection)
- **Synergy:** Plugs into existing hospital and emergency room distribution networks



Sales Forecast for ProbTBI®



*a forward-looking estimation

MEDICORTEX

Traction

3.5 M€
Private investments

4.9 M€
Grants

9 patents
7 in biomarker diagnostics, 2 in drug development

ProbTBI®
Urine test prototype

70 k€
Awards

Saliva test prototype
In development

Grant/Funding History

- 3 consecutive grants from the US Department of Defense, totaling USD 4.8M (currently Department of War)
- Received funding from EU Horizon 2020 SME Instrument Phase 1 (Grant #835546)



- Received funding from Business Finland
- Project funded by the Centre for Economic Development, Transport and the Environment (currently Centre for Economic Development)

Board of Directors: Medicortex International AB (publ)



Anna Tenstam
MSc, MBA

EXECUTIVE CHAIRMAN, NON-INDEPENDENT MEMBER

Served as a manager and board member in several companies



Adrian Harel
PhD, MBA

NON-INDEPENDENT MEMBER

Founder and CEO of Medicortex



Nils Grönberg
BA

INDEPENDENT MEMBER

Experienced executive in many companies and foundations



Ville Ranta-Panula
MSc, MBA

INDEPENDENT MEMBER

Experienced drug development and business development professional



Jesper Yrwing
BA

NON-INDEPENDENT MEMBER

Experienced executive with a background in finance, corporate leadership, and board work

Team: Medicortex Group



Adrian Harel PhD, MBA

CEO, FOUNDER



Jesper Yrwing BA

CFO



Lasse Välimaa PhD

CSO



Pihla Miettinen MSc

COO



Leonardo Lara-Valderrábano PhD

RESEARCH SCIENTIST



Begüm Utz PhD

PRODUCT MANAGER



Ivette Bañuelos-Cabrera PhD

SENIOR SCIENTIST

Medicortex on NGM

Ticker: MEDFIN B

Public Market Snapshot | October 2026

5,761 Shareholders	**30,983,024** Total shares
1.22 SEK Share price	**37.8M SEK** Market cap


Shareholder count as of 31 Aug 2026; share price and current value as of 1 Oct 2026.



Holdings and Assets

Company / Holding	Owned by	Ownership	Book Value
Dr. Hud International	Invest Riddarholmen 1802 AB	5.0%	500,000 SEK
Leikur Holding	Invest Riddarholmen 1802 AB	5.7%	4,000,000 SEK
Online Transaction Tech. Vent. Hold. (FXbet)	Invest Riddarholmen 1802 AB	10.0%	10,000 SEK
NoteCom holding (publ)	Invest Riddarholmen 1802 AB	5.9%	4,087,418 SEK
Co-Properties	Medicortex International AB	5.5%	8,234,096 SEK
Total			16,831,514 SEK

Holdings as of 30 September 2026



Thank You!

MEDICORTEX

Get in touch with us.

Dr Adrian Harel, CEO

adrian.harel@medicortex.fi

medicortex.eu